The Ovial Nutrition Kit is a complete 6-week nutritional system developed by surgeons to support orthopedic patients throughout their recovery journey. Designed to help prepare the body before surgery and optimize healing afterward, OVIAL focuses on the core biological needs of recovery: muscle preservation, inflammation support, tissue repair, nerve health, mobility, immune balance, and improved sleep quality.
Osteal Therapeutics
Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery. The company’s lead candidate, VT-X7 KIT, is in late-stage clinical development to treat periprosthetic joint infections, a serious complication of joint replacement surgery. For more information, please visit: www.ostealtx.com.
Onbe
The payouts gateway that enables clients to outsource their entire B2C disbursement operation, relieving them of the cost, complexity and risk that come with orchestrating these payments in-house, delivering context-driven payment choices that are instant, convenient and simple. | Onbe enables health-tech platforms and banks launch digital patient refunds that differentiate their offering, reduce operational and compliance risk and scale provider adoption.
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across development, treatment, and outcomes. OTX-TKI (also known as AXPAXLI™), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based technology. It is currently in Phase 3 clinical trials to advance wet age-related macular degeneration (AMD) and diabetic retinopathy (DR) treatment, aiming to improve long-term outcomes while reducing the frequency of injections. | Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions.
Oakwood Labs
Oakwood Labs is a specialized contract development and manufacturing organization (CDMO) focused on advanced drug delivery, with particular expertise in long-acting injectable (LAI) technology. The company develops and manufactures biodegradable polymer-based formulations—primarily using PLGA microspheres—that enable sustained, controlled release of small molecules, peptides, and proteins ranging from days up to a year. Leveraging deep scientific know-how and proprietary formulation platforms, Oakwood Labs supports pharmaceutical partners from early-stage development through commercial manufacturing. Its integrated CMO capabilities include formulation development, analytical services, scale-up, aseptic fill-finish, and regulatory support, making it a trusted partner for complex parenteral products that require precision, consistency, and extended-release performance.
NUVISAN
Your partner of choice in bringing therapeutics to life. Nuvisan is a full-service CRO and CDMO with state-of-the-art facilities in Germany and France, supporting pharmaceutical, biotech, venture capital and non-profit partners with high-quality, end-to-end solutions that accelerate the journey from early discovery to clinical development. With more than 40 years of heritage, Nuvisan has built a reputation for scientific excellence, industry expertise and seamless integration across discovery, development and manufacturing. Our centres of excellence, including drug discovery in Berlin, provide comprehensive capabilities to advance complex programs efficiently. In oncology, Nuvisan offers a comprehensive portfolio of specialised technologies and models designed to accelerate cancer therapeutic innovation. Our capabilities encompass target validation, CRISPR/RNAi screening, custom assay development, next-generation sequencing, single-cell analyses, multiplex flow cytometry, biomarker discovery and in vivo pharmacology including PK/PD and efficacy studies. With an extensive collection of cancer models and deep translational expertise, we support programs across solid tumours, hematologic malignancies, immuno-oncology and novel therapeutic modalities. By working collaboratively to adapt to each client’s unique needs, we help de-risk development and expedite the delivery of impactful oncology therapeutics to patients worldwide. | The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. | Your partner of choice in bringing therapeutics to life Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France. Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life. Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project. Discovery: Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration. Preclinical: Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic. CMC: Collaborating with you to advance molecules into drug products. Clinical: Providing tailored clinical solutions to fully assess your drug faster. Digital: Empowering your drug discovery and development with integrated data services, machine learning and generative AI. Research phases Supporting you with integrated, tailored solutions at every step of your drug discovery and development journey.
Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.
Novogene
Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the world. | Novogene is a global leader in Next-Generation Sequencing (NGS), Proteomics, and Metabolomics services, empowering researchers and organizations with cutting-edge multi-omics solutions. Since our founding in March 2011, we have remained at the forefront of innovation, delivering world-class services to advance discoveries in life sciences, healthcare, and beyond. With state-of-the-art laboratories and operations across the United States, the United Kingdom, Germany, China, Thailand, Korea, Singapore, and Japan, Novogene has established a strong global presence to support scientific advancements worldwide. At Novogene, we have built a highly skilled, interdisciplinary team, with the majority holding advanced degrees from top global institutions. Our high-throughput sequencing and high-performance computing platforms are designed to efficiently handle large-scale genomic data, meeting the evolving demands of life sciences and medical research with secure data storage and powerful bioinformatics analysis. Through extensive collaborations with leading academic institutions, hospitals, pharmaceutical companies, and agricultural enterprises, Novogene continues to shape the future of genomic research and precision medicine. As a trusted genomics partner, we are committed to empowering researchers worldwide with the technology, expertise, and solutions needed to advance genomics and improve life. | Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 45 NGS-related patents, as well as over 950 SCI articles with a total impact factor of more than 7970, including publications in first tiers journals such as Cell, Nature and Science. The UC Davis location of Novogene Corporation Inc. was opened in early 2016. We utilize Illumina platform to serve customers in North and South America, and we also offer PacBio and Nanopore services. Novogene Corporation Inc. is proud to have collaborated with scientists from the USA, Canada, Brazil, Colombia, Mexico, and so many more. We are excited to see this global collaboration and partnership growing. | Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 62 NGS-related patents, as well as nearly 20,000 SCI articles with a total impact factor of nearly 120,000, including publications in first-tier journals such as Cell, Nature and Science. As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands, and Japan, Novogene was founded in 2011 and has been growing rapidly over the past few years. Novogene has genomic sequencing labs in the US (at The University of California at Davis campus), China, Singapore, and the UK (Cambridge).
Novartis Pharmaceuticals
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. | Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.
Novaflow
Bioinformatics in minutes, not months. Novaflow gives biotechs, researchers, and clinicians the software and services to turn complex data analysis from a months-long bottleneck into a task that takes minutes. We work across the full range of life sciences data, including sequencing, other omics, imaging, microscopy, and more. Whether your team needs a self-serve platform or hands-on expert support, Novaflow adapts to how you work, so scientists can focus on discovery instead of wrestling with pipelines, file formats, and infrastructure. Researchers at leading institutions including Stanford, Mount Sinai, and USC already rely on Novaflow to accelerate their work, shortening timelines from initial data to actionable insight. If your organization is generating more data than your team can analyze, Novaflow is the bioinformatics partner built to close that gap.